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Abstract
Objective: Cytotoxic factor is a unique patho-
genesis-associated cytokine that is produced
in mice (mCF) and man (hCF) during dengue
virus infection. This study was undertaken to
investigate the prevalence of hCF and its
relationship to the duration and severity of
the illness, and to ascertain its role, if any, in
the pathogenesis of dengue fever (DF) and
dengue haemorrhagic fever (DHF). Methods:
Peripheral venous blood was collected from
the patients of various grades and on differ-
ent days after the onset of clinical illness.
Sera were collected from a total of 333 cases,
and analysed for the presence of hCF by inhi-
bition ELISA and dot blot tests. Result: The
positivity for hCF was 100% in cases of DHF
grades III and IV, while overall positivity was
seen in 295 out of 333 (88%) cases studied.
Sera collected from the 1st to the 20th day of
illness were positive for hCF. This was not
seen at later periods. A majority of cases
(52%) were below 15 years of age and peak
positivity of 96% was noticed in the age-
group of 11–15 years. The mean inhibition
value of the ELISA was lowest (40 B 8%) in
cases of DF and was highest (70 B 10%) in
DHF grade IV, and the peak titres were found
on the first 4 days of the illness. Conclusion:
The findings show the presence of hCF in the
majority of cases. It is detectable up to the
20th day of illness and may suggest an asso-
ciation of higher levels of hCF with the onset
and severity of the illness.
Introduction
During dengue virus infection a unique
cytokine, the cytotoxic factor, is produced
both in mice (mCF) and man (hCF) [1, 2].
mCF is produced by L3T4-positive T cells
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and has a molecular weight of 43 kD and an
isoelectric point of pH 6.5. The amino-termi-
nal sequence of mCF does not match so far (at
the data base till December 1996) with any of
the known proteins or cytokines [3; personal
unpublished data]. We have shown the pro-
duction of cytotoxic factor experimentally in
mice (mCF) only during dengue virus infec-
tion and not in others including an antigeni-
cally related Japanese encephalitis virus and
unrelated polio, Coxsackie or ECHO viruses,
a number of bacteria and mitogens [4]. mCF
is similar to hCF in most of the properties
including molecular mass, antigenicity, and
reaction of their mRNA to the same probe in
the Northern blot tests [5]. mCF induces an
influx of Ca2+ into the target cells and selec-
tively kills macrophages, helper T cells and
the cells capable of liberating histamine by
producing nitrite and respiratory burst, thus
forming peroxynitrite [6–11]. mCF is a patho-
genesis-related protein, capable of reproduc-
ing the pathological changes that are seen in
the cases of dengue fever (DF)/dengue haem-
orrhagic fever (DHF), for example increased
capillary permeability, cerebral oedema and
blood leucocyte changes [3, 12–14].
The presence of hCF was shown in the sera
of the cases of DF/DHF stored at AFRIMS,
Bangkok and it was purified and character-
ized [2]. An extensive epidemic of DHF oc-
curred in Northern India, including Delhi and
Lucknow, during August to November 1996.
This provided an opportunity to further ex-
tend the work by systematic studies to address
many important questions regarding the role
of hCF in cases of dengue, for example inci-
dence of hCF-positive cases and the relation-
ship of hCF with the age of the patients, dura-
tion and the severity of the illness. This report
describes the presence of hCF in the majority
of the cases of DF/DHF and may be related to
the severity of the disease.
Materials and Methods
Cases
During the epidemic the diagnosis of dengue virus
infection was suspected on the basis of the clinical pre-
sentation of a patient. All patients were subjected to
Hess’ test and the haematocrit and platelet counts were
measured. The specific diagnosis for dengue virus
infection was made by virus isolation and by the pres-
ence of virus-specific IgM. Only cases with established
specific diagnosis were included in the present study.
The patients were selected as they came (consecu-
tively) to the hospital without any bias. The study was
carried out on a total of 333 consecutive cases of DF/
DHF in whom diagnosis of dengue virus infection was
established either by virus isolation (in 4 cases dengue
type 2 virus was isolated) or by detection of the virus-
specific IgM (in 229 patients) in the sera [data to be
published]. The patients were either admitted to the
Gandhi Memorial and Associated Hospitals, Luck-
now, and Department of Pediatrics, All India Institute
of Medical Sciences, New Delhi or were referred
directly to this department. They were classified into
those with DF or DHF grades I, II, III or IV according
to the World Health Organization criteria [15]. For
control, 50 normal healthy individuals (the first five
decades of age had 10 individuals each), without histo-
ry of a febrile or any other illnesses in the previous 3
months (hCF is not detectable after the 3rd week of
illness), were included. The sera obtained from the
cases and controls were screened for the presence of
hCF by enzyme-linked immunosorbent assay (ELISA)
and dot blot tests.
Inhibition ELISA
The principle of the test was that hCF present in
the test sample bound with the antibody on the solid
phase and inhibited subsequent binding of the protein
A + HRP, thus indicating the presence of hCF. The
technique was described elsewhere [16]. Briefly, a
1:5,000 dilution of hCF-specific antibody raised in
mice [2] was put on the solid phase. The controls
included were purified hCF as positive control and a
heterologous protein as negative control. The OD from
wells coated with antibody without addition of any
antigen was considered as 100% binding of the protein
A + HRP, while the wells without antibody coating
yielded values for the blank. The percent inhibition
was calculated as follows: % inhibition = 100 – (OD
with test sample – OD of blank)/(OD without test sam-
ple – OD of blank) ! 100 [2]. The mean value + 2 SD
obtained from the 50 normal healthy controls was
30%, and was considered as the ‘cut-off’ value.
DF
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Table 1. Presence of hCF in the sera from cases with
various grades of dengue illness
Grades
of
illness
Patients
n
hCF-positive patients, n (%)
dot blot ELISA
127 100 (79) 102 (80)
DHF I 25 22 (88) 21 (84)
DHF II 139 111 (80) 111 (80)
DHF III 24 24 (100) 24 (100)
DHF IV 18 18 (100) 18 (100)
Table 2. Presence of hCF in the sera collected on dif-
ferent days after the onset of dengue illness
Days
of
illness
Patients
n
hCF-positive patients, n (%)
dot blot ELISA
6 6 (100) 6 (100)
2 12 12 (100) 12 (100)
3 25 24 (96) 25 (100)
4 30 28 (93) 28 (93)
5 60 47 (78) 48 (80)
6 33 27 (82) 28 (85)
7 40 29 (73) 34 (85)
8 34 29 (87) 28 (84)
9 18 14 (81) 15 (83)
10 18 14 (81) 15 (83)
11–15 34 27 (81) 27 (81)
16–20 13 7 (54) 6 (46)
21–26 10 0 (0) 0 (0)
Table 3. Presence of hCF in the sera from cases of var-
ious age-groups
Age-groups, years Patients Positive, %
0–5 64 89
6–10 88 93
11–15 23 96
16–20 42 83
21–30 64 87
31–40 33 85
41 and above 19 84
Immunoblotting
The technique described earlier was used [2, 17].
Briefly, the sera were diluted tenfold in phosphate-
buffered saline, pH 7.2, and 100 Ìl of it was blotted on
nitrocellulose paper in Milliblot system (Millipore,
USA). The blots were dried in air, blocked with 3%
bovine serum albumin prepared in 0.1 M Tris-HCl,
pH 7.5. After thorough washing with phosphate-buf-
fered saline containing 0.05% Tween 20, the blots were
developed using anti-hCF antibody. For controls, the
blots were treated with anti-dengue virus antibody or
normal mouse sera in place of anti-hCF antisera.
Results
Presence of hCF in the Sera
The findings of ELISA and dot blot tests in
the sera from 333 cases of different grades of
illness show that the two tests gave similar
results, and 295 out of the 333 sera (88%)
were positive (table 1). All the sera from DHF
grade III and IV cases were positive for hCF,
while lowest positivity of 79% (100 out of 127
sera) was found in cases of DF grade. hCF was
present from day 1 to 20 of the illness (ta-
ble 2). At later periods (days 21–26) all the 10
sera were negative.
The data of the dot blot test for the agewise
distribution of hCF-positive cases have been
analysed (table 3) and show that 152 (46%)
patients were below 10 years of age and
among them 140 (92%) were positive for hCF.
Only 1 child was below 1 year of age (8
months old). The highest positivity of 96%
was found in children aged 11–15 years. Only
4 patients were above 51 years and the eldest
was 57 years old. The findings showed no sig-
nificant difference (p 1 0.05) in the positivity
for hCF in different age-groups. The study
included 208 males (90% positive) and 125
(92% positive) females.
The data was further analysed in relation
to the value of inhibition ELISA and the grade
of illness to get a rough indication of relation-
ship if any of the amount of hCF with the
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severity of illness. The findings summarized
in figure 1 show that the mean value in the
normal healthy controls was 20 B 5%.
Among the cases, the lowest value of 40 B 8%
was seen in DF. It gradually increased in cases
of DHF, the highest being 70 B 10% in DHF
grade IV. A similar analysis in relation to the
day of illness showed peak production of hCF
during the first 4 days of the illness.
Discussion
The findings of the present study demon-
strate the presence of hCF in 88% of the
serum samples of the cases of DF and DHF.
The presence of hCF in the serum was de-
tected by ELISA and was confirmed by the
dot blot tests in all the cases, and by the West-
ern blot test in some of the cases by the tech-
nique described earlier [2].
In a study carried out on the sera of 220
cases of DF/DHF at Bangkok, the presence of
hCF was shown in 98 (44%) of them by the
dot blot test [2] while the positivity was over
90% in the present study. In the Bangkok
study, the sera used were stored for 2–3 years
and had undergone repeated cycles of freezing
and thawing and some of them had precipi-
tates as well. In the present study, most of
them were tested almost immediately after
collection and a few of them had undergone
one cycle of freeze and thaw. It is well known
that repeated freezing and thawing is detri-
mental for any cytokine and therefore, fresh
samples are the best. Further it has been
shown that mCF aggregates on freezing [per-
sonal data]. The anti-mCF antibodies used in
the earlier study [2] cross-react with hCF in
ELISA, dot blot, Western blot and neutraliza-
tion of the cytotoxicity tests [5, 17], but the
anti-hCF antibody used in the present study
may react more avidly giving better results.
These points may explain the apparent dis-
Fig. 1. Mean values of inhibition ELISA in the sera
from controls and cases with various grades of illness.
The bars over the column represent BSD and the fig-
ures in parentheses represent the total number of cases
in each group.
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crepancy in the results of the two studies. Of
course the best would be the use of monoclo-
nal antibody.
A confirmation of the present study is pro-
vided by the data presented elsewhere that
show: (i) direct demonstration of the ex vivo
production of hCF by CD4-positive T cells in
peripheral blood mononuclear cells (PBMC)
of the majority of the cases of DF/DHF; (ii) in
situ demonstration of hCF in PBMC by fluo-
rescent antibody test, and by (iii) demonstra-
tion of hCF-specific mRNA in the CD4-posi-
tive T cells of the PBMC by Northern hybridi-
zation [18, 19]. The normal healthy controls
chosen for the present study represented the
age-groups of the patients and 10 each were in
each of the first five decades of life. The back-
ground of the findings so far that the cytotoxic
factor is produced only during dengue virus
infection [4] served to substantiate the ab-
sence of hCF in healthy individuals. We have
looked for hCF-specific mRNA in the PBMC
of these individuals and found it absent in all
of them [18, 19].
Mice inoculated with dengue virus intra-
peritoneally produce cytotoxic factor (mCF)
which is detectable on the 5th–6th day after
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infection, reaches a peak on the 9th–11th day,
and then gradually declines and is not detect-
able after the 16th day after infection [14].
This is supported by the present finding
which showed the presence of hCF in the sera
from the 1st day of illness to the 20th day with
peak amounts of hCF during the first 4 days
and then declined. In both mice and man, the
peak levels of mCF/hCF are associated with
the appearance of the clinical illness and have
a similar time course, considering the expo-
sure of the body during the incubation period
in man.
mCF/hCF are unique cytokines that are
seen only during dengue virus infection and
not during infection with a closely related
Flavivirus, the Japanese encephalitis virus, or
unrelated agents like various enteroviruses,
various mitogens, sheep erythrocytes, and
bacteria, e.g. salmonella etc. Further, the N-
terminal sequence of mCF has no homology
with any of the known proteins or cytokines
[3, 4; personal unpublished data]. Therefore,
can hCF be an indicator of dengue virus infec-
tion and be used for the diagnosis of dengue?
Difficulties encountered in rapid and reliable
diagnosis of dengue have prompted us to ini-
tiate exploration of this possibility, using hCF
purified from the sera of the cases or the
recombinant hCF produced by its cDNA li-
brary prepared in Ïgt11 and expressed in
Escherichia coli to produce monoclonal anti-
body against hCF [personal unpublished
data].
mCF is a pathogenesis-related cytokine
and produces pathological lesions in mice that
are seen in human cases of DHF, for example,
increased capillary permeability [12], cerebral
oedema [14] and alterations in the number
and functions of leucocytes [13]. Purified hCF
obtained from the cases of DHF produces
increased capillary permeability and damages
the blood-brain barrier on inoculation in mice
[2]. hCF may have a role in the pathogenesis
of DHF as indicated in the present study:
(i) higher levels of hCF are associated with the
onset of clinical illness; (ii) higher levels of
hCF are found in cases with severe disease,
the DHF grade IV as compared to mild DF
(p ! 0.001). Admittedly, the method used to
assess the amount of hCF is not accurate,
therefore, precise studies are needed to un-
equivocally establish this fact. The number of
hCF-producing CD4-positive T cells in the
blood of DHF cases may not reflect the
amount of secreted hCF [18, 19]. Therefore,
the factors that control the levels of hCF need
careful study.
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